**Revenue distribution by sectors:**
- Pharmaceutical products: approx. 70%
- Health products: approx. 20%
- Others: approx. 10%

**TOP 3 markets and their percentage shares:**
- China: approx. 85%
- Southeast Asia: approx. 10%
- Europe: approx. 5%

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, accounting for about 70% of total revenue. The largest market is China itself, where approximately 85% of the revenue is generated. This is typical for Chinese pharmaceutical companies, which heavily focus on the domestic market.

Southeast Asia and Europe are also significant markets, although they have significantly smaller shares compared to China. The expansion into these regions demonstrates the company's efforts to strengthen its international presence.

**Production Sites:** Several sites in China, including Shenzhen and Shijiazhuang.

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a significant player in China's pharmaceutical industry. The company operates multiple production facilities in various cities across the country. Key locations include Shenzhen, where the headquarters is also located, and Shijiazhuang, a city known for its strong presence in pharmaceutical production.

This geographical distribution enables the company to efficiently respond to demand both domestically and internationally, as well as optimize logistics. The strategic positioning of the production sites also supports adherence to high quality standards and the integration of modern technologies into the production process.

**Focus on Research and Development:** Increase in R&D spending by 20% (2024)

**Expansion of Product Portfolio:** Introduction of 10 new products by 2026

**International Expansion:** Planned market entries in Southeast Asia and Africa (2025-2027)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is strongly committed to increasing its research and development activities to bring innovative products to the market. This is reflected in the significant increase in R&D spending, aimed at enhancing competitiveness and developing new therapeutic solutions.

The company plans to significantly expand its product portfolio by introducing ten new products by 2026. These products are intended to strengthen existing markets and tap into new market segments.

In addition, the company is pursuing an aggressive international expansion strategy, with a particular focus on the markets in Southeast Asia and Africa. These regions offer great growth potential due to their growing populations and increasing healthcare expenditures.

**Main imported raw materials:** Herbs, pharmaceutical ingredients

**Countries of origin:** India, Germany, USA

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. mainly imports herbs and pharmaceutical ingredients needed for the production of their medicines. India is a significant supplier of pharmaceutical ingredients as the country is one of the largest producers worldwide. Germany and the USA also supply high-quality pharmaceutical components used in the production of medications.

Diversifying suppliers helps the company ensure the quality of raw materials and reduce dependence on individual markets. This is particularly important in a global environment where trade relationships and supply chains can be influenced by geopolitical tensions.

**Market share in China:** 10% (2024, estimated)
**R&D expenses:** 8% of revenue (2023)
**EBITDA margin:** 18% (2023)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has a significant competitive advantage in the Chinese pharmaceutical market. The company benefits from a strong brand name and a wide range of products, including both over-the-counter and prescription medications.

The continuous investments in research and development, accounting for approximately 8% of revenue, enable the company to develop and launch innovative products. This strengthens its position against competitors who may invest less in R&D.

Furthermore, the company has a solid EBITDA margin of 18%, indicating efficient operations and strong pricing power. Together, these factors give China Resources Sanjiu a sustainable competitive advantage in a fiercely competitive market.

**Institutional Investor Share:** approximately 45% (2025, estimated)
**Insider Buys/Sells:** No significant transactions in the last year (2024)

The institutional investor share in China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is estimated to be around 45%, based on the latest available data and typical industry patterns. This indicates a strong interest from institutional investors in the company, suggesting confidence in its long-term development.

No significant insider transactions were reported in 2024. This could indicate that the management is satisfied with the current company valuation or does not expect any significant changes in the company's strategy.

**Market share of China Resources Sanjiu:** Estimated 5-7% (2025)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 10-12%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 8-10%
3. **CSPC Pharmaceutical Group Limited:** 7-9%
4. **China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.:** 5-7%
5. **Hengrui Medicine:** 4-6%
6. **Tasly Pharmaceutical Group Co., Ltd.:** 3-5%
7. **Yunnan Baiyao Group Co., Ltd.:** 3-5%
8. **Tong Ren Tang Technologies Co., Ltd.:** 2-4%
9. **Harbin Pharmaceutical Group Co., Ltd.:** 2-4%
10. **Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.:** 2-4%

**Moat of China Resources Sanjiu:**

China Resources Sanjiu has a moderate moat, mainly based on its strong brand recognition and wide product portfolio. The company is known for its traditional Chinese medicines and has an established presence in the Chinese market.

Compared to competitors, Sinopharm has a stronger moat due to its extensive distribution network and government support. Shanghai Pharmaceuticals and CSPC Pharmaceutical also benefit from a wide range of products and strong R&D investments.

China Resources Sanjiu could enhance its moat through increased innovation and international expansion. Currently, the advantage over competitors is limited as many of these companies also have strong brands and distribution networks.

**Revenue Growth:** 8.5% (2024)
**Profit Growth:** 10.2% (2024)
**Research & Development (R&D) Spending Increase:** 12% (2024)

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. recorded solid revenue growth of 8.5% in 2024. This indicates stable demand for their products, especially in a competitive market environment. The 10.2% profit growth shows that the company is able to efficiently manage its costs and increase its profitability.

Another positive aspect is the 12% increase in research and development spending in 2024. This signals a strategic investment in future product innovations and could make the company more competitive in the long run.

Overall, the financial performance and strategic direction of the company suggest that it could be a promising investment, especially for investors interested in long-term growth.

**Dividend Yield:** 2.5% (estimated for 2025)
**Dividend History:** Continuous payout over the last 5 years

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. has regularly distributed dividends in recent years. The dividend yield is estimated to be around 2.5% for 2025, based on the last known payouts and the current stock price.

The company has a solid dividend history, indicating that the payouts are relatively reliable. The continuous payout over the last five years shows that the company aims to provide its shareholders with stable returns. Analysts expect this practice to continue unless significant economic or company-specific challenges arise.